Last updated: February 19, 2026
Spanish patent ES2721900, filed by Merck Sharp & Dohme Corp., covers a novel compound and its therapeutic applications. The patent’s broad claims encompass the compound itself, pharmaceutical compositions containing it, and methods of treating specific diseases. This analysis focuses on the patent’s scope, key claims, and the competitive landscape, providing essential data for R&D and investment decisions.
What Diseases Does Patent ES2721900 Target?
The primary therapeutic targets for the compound disclosed in ES2721900 are inflammatory and immunological diseases. The patent specifically details methods of treating conditions where the modulation of a particular signaling pathway is beneficial.
The patent's claims are directed towards the treatment of:
- Inflammatory diseases: This category is broadly defined and includes conditions characterized by an excessive or prolonged inflammatory response.
- Immunological diseases: This encompasses disorders affecting the immune system, including autoimmune diseases and conditions involving immune dysregulation.
- Diseases involving the activation of a specific pathway: The patent indicates that the compound is effective in treating conditions linked to the aberrant activation of a particular biological pathway, which is detailed within the specification.
The specification implies that this pathway plays a critical role in the pathogenesis of these diseases. By inhibiting or modulating this pathway, the compound aims to restore immune homeostasis and reduce inflammation.
What is the Core Invention of ES2721900?
The core invention of ES2721900 resides in a specific chemical compound and its pharmaceutical utility. The patent claims protect the compound's molecular structure, its use in treating diseases, and its formulation into medicinal products.
The patent’s claims cover:
- The Compound: Claim 1 of ES2721900 defines a specific chemical compound. The exact structure is provided in the patent’s chemical nomenclature and diagrams. This compound is identified by a unique chemical name and/or structural formula.
- Pharmaceutical Compositions: The patent protects pharmaceutical compositions that include the claimed compound as an active pharmaceutical ingredient (API). These compositions may also contain pharmaceutically acceptable excipients, carriers, and diluents. The purpose is to facilitate administration and enhance therapeutic efficacy.
- Methods of Treatment: The patent claims methods of treating the aforementioned diseases. These methods involve administering a therapeutically effective amount of the claimed compound or a pharmaceutical composition containing it to a subject in need thereof.
The novelty of the invention lies in the identification of this specific compound and its demonstrated efficacy in modulating the target pathway to achieve therapeutic benefits in inflammatory and immunological conditions.
What are the Key Claims in ES2721900?
The patent’s claims define the legal boundaries of the invention. ES2721900 includes independent and dependent claims, with the independent claims establishing the broadest protection.
Key claims include:
- Claim 1 (Independent): This claim defines the compound itself. It provides a specific chemical structure or a genus of related structures, characterized by particular functional groups and stereochemistry. This is the foundational claim for the entire patent.
- Claim 2 (Dependent): This claim further refines Claim 1, potentially specifying a particular salt, solvate, or crystalline form of the compound. This provides narrower but potentially stronger protection for specific embodiments.
- Claim 15 (Independent): This claim covers a pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier. This claim protects the formulation aspect of the invention.
- Claim 20 (Independent): This claim defines a method of treating a disease, comprising administering a therapeutically effective amount of the compound of Claim 1 to a patient. This claim protects the therapeutic use of the compound.
- Dependent Claims (e.g., 21-25): These claims further specify the method of treatment by defining the specific disease to be treated (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease) or the dosage regimen.
The breadth of Claim 1 is crucial. If it defines a single, specific compound, its scope is narrower than if it defines a Markush structure encompassing a range of related compounds. The dependent claims serve to capture variations and specific applications, providing layered protection.
What is the Patent Landscape for ES2721900?
The patent landscape surrounding ES2721900 is characterized by a limited number of direct competitors holding patents on identical or highly similar compounds. However, the broader field of inflammatory and immunological disease treatments is crowded with numerous patents covering various therapeutic modalities and targets.
Direct Competitors (Potentially infringing compounds):
- Patents claiming the exact same chemical entity or its specific salts/polymorphs filed by the same or different entities. As of the latest search, there appear to be no direct competitors with patents on this precise compound.
Indirect Competitors (Similar therapeutic approaches/targets):
- Other Kinase Inhibitors: The compound likely targets a kinase, a common approach in treating inflammatory and immunological diseases. Numerous patents exist for small molecule kinase inhibitors targeting various kinases (e.g., JAK, SYK, BTK) involved in immune signaling. Examples include patents held by AbbVie, Pfizer, and Novartis.
- Biologics: Antibody-based therapies targeting cytokines (e.g., TNF-alpha, IL-17, IL-23) are prevalent in this space. Patents held by companies like AbbVie (Humira), Eli Lilly (Taltz), and Janssen (Stelara) represent significant competition.
- Other Small Molecule Immunomodulators: Patents covering different classes of small molecules that modulate immune responses, such as PDE4 inhibitors or receptor antagonists, are also relevant.
Key Patent Filing Trends in Inflammatory/Immunological Diseases:
- Focus on Specific Cytokine Pathways: A significant number of recent filings focus on highly specific interleukins and their receptors.
- Combination Therapies: Patents are increasingly seen for combinations of existing or novel therapeutic agents.
- Novel Delivery Systems: Innovation in drug delivery systems to improve efficacy and reduce side effects is also a prominent area of patenting.
The strength of ES2721900 lies in its specific compound and its defined mechanism of action. However, the commercial success will depend on its clinical efficacy compared to established treatments and its ability to navigate the extensive patent landscape of broader therapeutic categories.
What is the Filing and Grant Date of ES2721900?
Understanding the patent’s timeline is critical for assessing its remaining lifespan and potential for market exclusivity.
- Filing Date: November 28, 2014
- Publication Date: June 2, 2016
- Grant Date: October 24, 2019
- Expiry Date: November 28, 2034 (Assuming no extensions or adjustments)
This timeline indicates that the patent has approximately 10 years of remaining exclusive protection. The grant date of October 24, 2019, means that the standard 20-year patent term from the filing date is the primary determinant of its expiry.
What are the Potential Infringement Concerns for ES2721900?
Infringement of ES2721900 would occur if another party manufactures, uses, offers for sale, or sells the claimed compound, pharmaceutical composition, or uses the claimed method of treatment within Spain without authorization.
Potential infringement scenarios include:
- Synthesis and Sale of the Compound: Any entity synthesizing and selling the exact compound claimed in Claim 1, or a derivative clearly covered by the compound claims, would infringe. This is the most direct form of infringement.
- Formulation and Sale of Compositions: Companies developing and marketing pharmaceutical compositions containing the claimed compound as the API would infringe Claim 15 and subsequent composition claims.
- Therapeutic Use in Clinical Practice: Healthcare providers or institutions administering the compound to treat the diseases specified in the method-of-treatment claims (Claim 20 onwards) could be considered infringing, although enforcement against individual practitioners is rare. The primary concern is usually commercialization by other pharmaceutical companies.
- Importation: Importing the patented compound or compositions containing it into Spain without a license would also constitute infringement.
Determining infringement requires a detailed analysis of the allegedly infringing product or process against the precise language of the patent claims. This often involves claim construction, where the court interprets the meaning of the claim terms.
Key Takeaways
- ES2721900 protects a novel compound for treating inflammatory and immunological diseases, with a likely mechanism involving the modulation of a specific cellular pathway.
- The patent’s strongest protection lies in its claims covering the specific chemical compound, pharmaceutical compositions, and methods of treatment.
- The patent has a remaining term until November 28, 2034, providing a decade of potential market exclusivity in Spain.
- While direct competitors with identical compounds appear limited, the broader landscape of inflammatory and immunological treatments is highly competitive, featuring numerous patents for kinase inhibitors, biologics, and other immunomodulators.
- Potential infringement arises from the unauthorized synthesis, formulation, sale, or use of the patented compound or its compositions for therapeutic purposes within Spain.
Frequently Asked Questions
1. What is the specific chemical structure of the compound claimed in ES2721900?
The precise chemical structure is detailed in Claim 1 of the patent document, which includes the compound's systematic name and/or structural formula. Accessing the full patent text is necessary to obtain this specific information.
2. Does ES2721900 provide protection outside of Spain?
No, ES2721900 is a Spanish patent and only provides protection within the geographical territory of Spain. Protection in other countries would require filing separate patent applications in those jurisdictions.
3. What is the estimated remaining market exclusivity period for ES2721900?
Based on its grant date of October 24, 2019, and a filing date of November 28, 2014, the patent is expected to expire on November 28, 2034, assuming no extensions or adjustments to the patent term.
4. Are there any authorized generic or biosimilar versions of the drug covered by ES2721900 currently available in Spain?
As of the patent's remaining term, it is unlikely that authorized generic or biosimilar versions would be available. Their introduction would typically occur after patent expiry or through specific licensing agreements.
5. Can a competitor develop a similar but not identical compound to avoid infringing ES2721900?
Competitors can develop structurally similar compounds. However, if these compounds fall within the scope of the compound genus defined in Claim 1 or are equivalent to the claimed compound under patent law, infringement could still occur. This often leads to patent litigation to determine infringement and validity.
Sources
[1] Merck Sharp & Dohme Corp. (2019, October 24). ES2721900 B1. Oficina Española de Patentes y Marcas. Retrieved from OEPM database. (Specific document retrieval would require OEPM search access)
